Current Addiction Reports
February 27, 2026
Amanda C. Lee, Jibran Y. Khokhar
Purpose of Review The association between cannabis use and schizophrenia is a growing public health concern, particularly in vulnerable populations. This review synthesizes insights from recent studies to investigate how preclinical rodent models can help clarify this relationship. Recent Findings Increasingly advanced paradigms have been developed, including various translationally-relevant...
Biomolecules
September 18, 2025
Hakan Kayır, Larissa Kouroukis, Iman Aziz et al.
2 citations
Delta-9-Tetrahydrocannabivarin (THCV), a naturally occurring cannabinoid and structural analog of THC, exhibits a dual pharmacological profile as a CB1 receptor agonist/antagonist and a partial CB2 agonist. This study evaluated the effects of THCV in a THC discrimination model in rats. Male Sprague-Dawley rats (n = 16, 300–340 g, PND60) were trained under a fixed ratio 20 (FR20) schedule to...
Schizophrenia Bulletin
June 20, 2024
Mary F. Brunette, Robert M. Roth, Christi L. Trask et al.
5 citations
BACKGROUND AND HYPOTHESIS: Up to 43% of people with schizophrenia have a lifetime cannabis use disorder (CUD). Tetrahydrocannabinol (THC) has been shown to exacerbate psychosis in a dose-dependent manner, but little research has assessed its effects on schizophrenia and co-occurring CUD (SCZ-CUD). In this double-dummy, placebo-controlled trial (total n = 130), we hypothesized that a modest dose...
Current Topics in Behavioral Neurosciences
2022
Hakan Kayır, Jessica Ruffolo, Patrick McCunn et al.
15 citations
America and across the globe. Cannabis use has multifaceted impacts on cognition in schizophrenia patients and healthy subjects. Healthy subjects, particularly those who initiated cannabis use at earlier ages and used high-potency cannabis for longer durations, exhibited poorer cognition mainly in working memory and attention. Cannabis use in schizophrenia has been associated with symptom...
Schizophrenia Research
April 1, 2018
Susan Whitfield-Gabrieli, Adina S Fischer, Angela Henricks et al.
Nearly half of patients with schizophrenia (SCZ) have co-occurring cannabis use disorder (CUD), which has been associated with decreased treatment efficacy, increased risk of psychotic relapse, and poor global functioning. While reports on the effects of cannabis on cognitive performance in patients with SCZ have been mixed, study of brain networks related to executive function may clarify the...